Roche Tecentriq plus Avastin cuts return of adjuvant liver cancer in Phase 3

 

• In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1
• Up to 80% of people with this type of HCC experience disease recurrence, at which point they are faced with poorer prognosis and shorter survival2
• These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 and included in the official press programme

https://www.globenewswire.com/news-release/2023/04/16/2647456/0/en/Roche-s-Tecentriq-plus-Avastin-reduced-the-risk-of-cancer-returning-in-people-with-certain-types-of-adjuvant-liver-cancer-in-a-Phase-III-study.html